1.	Phase III Randomized Study of Decitabine Versus Supportive Care in Patients With Advanced Myelodysplastic Syndromes Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SUPERGEN-D-0007, ABCCC-010303, NCT00043381
2.	Phase III Randomized Study of Low-Dose Decitabine Versus Standard Supportive Care in Elderly Patients With Myelodysplastic Syndromes Phase: Phase III Type: Treatment Status: Closed Age: 60 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: EORTC-06011, SUPERGEN-EORTC-06011, GMDSG-EORTC-06011, NCT00043134, EudraCT-2005-002830
3.	Phase I/II Study of Chemotherapy with High-Dose Decitabine, Busulfan, and Cyclophosphamide with Allogeneic Stem Cell Transplantation in Patients With Hematologic Malignancies (Summary Last Modified 07/2000) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 15 to 55 Sponsor: NCI Protocol IDs: MDA-DM-94064, NCI-G96-0999, NCT00002831
4.	Phase I/II Trial of Decitabine and Allogeneic Peripheral Blood Stem Cells Transplantation in Patients With Relapse Post Allogeneic Bone Marrow Transplantation (Summary Last Modified 07/2000) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 60 and under Sponsor: NCI Protocol IDs: MDA-DM-94077, NCI-G96-1000, NCT00002832
5.	Phase II Study of Decitabine in Hormone-Refractory Stage D2 Prostate Cancer (Summary Last Modified 11/94) Phase: Phase II Type: Treatment Status: Completed Age: over 18 Sponsor: Protocol IDs: NCI-94-C-0002A, NCI-CPB-332
6.	Phase II Study of Decitabine for Myelodysplastic Syndromes (Summary Last Modified 12/2001) Phase: Phase II Type: Treatment Status: Closed Age: 15 and over Sponsor: NCI Protocol IDs: MSKCC-98017, NCI-G98-1444, NCT00003361
7.	Phase II Chemotherapy with 5-Aza-dCyd in Patients with Recurrent or Metastatic Squamous Cell Cancer of the Uterine Cervix (Summary Last Modified 05/89) Phase: Phase II Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Protocol IDs: EORTC-55857
8.	Phase II Trial of 5-Aza-2'-deoxycytidine in Patients with Advanced Squamous Cell Carcinoma, Adenocarcinoma, and Large Cell Carcinoma of the Lung Phase: Phase II Type: Treatment Status: Closed Age: 75 and under Sponsor: Protocol IDs: EORTC-16851C
9.	Phase II Chemotherapy with 5-AZA-2'-Deoxycytidine in Patients with Relapsed or Refractory Stage III/IV Hodgkin's Disease Phase: Phase II Type: Treatment Status: Closed Age: over 15 Sponsor: Protocol IDs: EORTC-20861
10.	Phase II Study of Chemotherapy with 5-Aza-2'-Deoxycytidine in Patients with Advanced Epithelial Cancer of the Ovary Phase: Phase II Type: Treatment Status: Closed Age: 70 and under Sponsor: Protocol IDs: EORTC-16851G
11.	Phase II Chemotherapy with 5-Aza-2'-deoxycytidine in Patients with Nonseminomatous Testicular or Extragonadal Germ Cell Tumors That Are Progressive, Measurable, and Metastatic (Summary Last Modified 05/88) Phase: Phase II Type: Treatment Status: Closed Age: any age Sponsor: Protocol IDs: EORTC-30871
12.	Phase II Randomized Trial of 5-Aza-2'-deoxycytidine in Combination with m-AMSA or IDA in Patients with Relapsed Acute Leukemia (Summary Last Modified 05/91) Phase: Phase II Type: Treatment Status: Closed Age: 14 to 70 Sponsor: Protocol IDs: EORTC-06893
13.	Phase II Study of Imatinib Mesylate and Decitabine in Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia Phase: Phase II Type: Treatment Status: Completed Age: Any age Sponsor: NCI Protocol IDs: MDA-ID-02205, NCI-5737, NCT00054431, 5737
14.	Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) Phase: Phase II Type: Treatment Status: Closed Age: Not specified Sponsor: Other Protocol IDs: ID03-0180, NCT00067808
15.	Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Phase: Phase II Type: Treatment Status: Temporarily closed Age: 18 and over Sponsor: NCI Protocol IDs: MDA-2003-0308, 5954, NCI-5954, NCT00085293
16.	Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure Phase: Phase II Type: Treatment Status: Completed Age: Not specified Sponsor: Other Protocol IDs: 2004-0468, NCT00113321
17.	A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DACO-020, NCT00260065
18.	Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML) Phase: Phase II Type: Treatment Status: Closed Age: 60 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DACO-017, NCT00358644
19.	Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 2006-0962, NCT00561912
20.	Phase I Study of the Biologic and Clinical Effects of Decitabine (5-Aza-2'Deoxycytidine; DAC) in Patients with Advanced Malignancies Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: LAC-USC-0C963, NCI-T95-0070, NCT00002980, T95-0070
21.	Phase I Study of Decitabine-Mediated Induction of Tumor Antigen and Tumor Suppressor Gene Expression in Patients With Unresectable Lung or Esophageal Cancer or Malignant Pleural Mesothelioma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-99-C-0129, NCI-T99-0012, T99-0012, NCT00019825
22.	Phase I Study of Decitabine in Patients With Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: LAC-USC-0C0101, NCI-5353, NCT00030615
23.	Phase I Study of Decitabine in Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Phase: Phase I Type: Treatment Status: Completed Age: Under 22 Sponsor: NCI Protocol IDs: COG-ADVL0114, ADVL0114, NCT00042796
24.	Phase I Study of Decitabine in Patients With High-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: PMH-PHL-004, NCI-5591, NCT00049582, 5591
25.	Phase I Study of Decitabine, Doxorubicin, and Cyclophosphamide in Children With Relapsed or Refractory Solid Tumors or Neuroblastoma Phase: Phase I Type: Treatment Status: Completed Age: Over 12 months to 21 years Sponsor: NCI Protocol IDs: COG-ADVL0215, ADVL0215, NCT00075634